Areti Philotheou

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Simon Heller, John B. Buse, Miles Fisher et al. · The Lancet · 2012 · 401 citations

Type 1, Diabetes Management, Insulin Degludec +7

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

Bo Åhrén, Irl B. Hirsch, Thomas R. Pieber et al. · Diabetes Care · 2016 · 229 citations · Full text

Long‐term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat‐to‐target basal–bolus regimen with insulin aspart at meals: a 2‐year, randomized, controlled trial

Paul C. Bartley, M. Bogoev, Julie Rask Larsen et al. · Diabetic Medicine · 2008 · 159 citations · Full text

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

Thomas R. Pieber, H‐C. Treichel, B. Hompesch et al. · Diabetic Medicine · 2007 · 127 citations

No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes

Markus Walter, Areti Philotheou, F Bonńici et al. · Diabetes Care · 2009 · 115 citations · Full text